Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults

Antimicrob Agents Chemother. 2011 Jul;55(7):3240-3. doi: 10.1128/AAC.01680-10. Epub 2011 May 16.

Abstract

The physiochemical properties of levofloxacin suggest that it is an agent which may exhibit altered pharmacokinetics in obese individuals. The purpose of this study was to describe the pharmacokinetics of a single 750-mg intravenous dose of levofloxacin in both hospitalized and ambulatory obese individuals. The hypothesis was that a standard dose of levofloxacin in obese individuals would achieve serum concentrations likely to be therapeutic. A single levofloxacin dose of 750 mg was infused over 90 min, and seven serial serum samples were subsequently obtained to evaluate the pharmacokinetics after the first dose. The peak concentrations of levofloxacin were comparable to those seen with normal-weight individuals. However, the area under the concentration-time curve and clearance were quite variable. Accelerated clearance was evident in the ambulatory obese individuals. Further investigation of the effects of obesity on the pharmacokinetics of levofloxacin is necessary to ensure optimal dosing.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / blood
  • Anti-Bacterial Agents / pharmacokinetics*
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Intravenous
  • Levofloxacin*
  • Male
  • Middle Aged
  • Obesity / physiopathology*
  • Ofloxacin / administration & dosage*
  • Ofloxacin / blood
  • Ofloxacin / pharmacokinetics*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Levofloxacin
  • Ofloxacin